<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01004510</url>
  </required_header>
  <id_info>
    <org_study_id>US CZOL446EUS143T</org_study_id>
    <nct_id>NCT01004510</nct_id>
  </id_info>
  <brief_title>Zometa Adjuvant Treatment of Malignant Pleural Effusion Due To Non-Small Cell Lung Cancer</brief_title>
  <acronym>ZAP</acronym>
  <official_title>An Open-Label Phase II Study of Zometa as Adjuvant Treatment of Malignant Pleural Effusion Due to Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peter Bushunow MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Rochester General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether the addition of the bisphosphonate Zometa
      (zoledronic acid) used along with standard regimens of chemotherapy, will help to control the
      need for palliative intervention of malignant pleural effusions due to non-small cell lung
      cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Malignant pleural effusions are common in late stage non-small cell lung cancer and can lead
      to significantly increased morbidity in this patient population. The majority of patients are
      symptomatic due to their malignant effusions. The recurrence rates are thought to be quite
      high overall and may approach 100% without any further treatment.Currently there is no
      available non-invasive, medical means for controlling the effusions other than systemic
      chemotherapy.Zoledronic acid has been shown in a mouse model of malignant pleural effusion to
      decrease fluid accumulation and tumor dissemination while prolonging survival.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    failure to accrue projected number of patients
  </why_stopped>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Control (Lack of Need for Palliative Intervention of Malignant Pleural Effusions) in Patients With Non Small Cell Lung Cancer Treated With Standard Regimens of Cytotoxic Chemotherapy With the Addition of Zometa</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Malignant Pleural Effusion</condition>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Zoledronic Acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Zometa administered as a 15 minute IV infusion of either 4 mg, 3.5mg, 3.3 mg or 3.0 mg every 4 weeks based on the patient's baseline calculated creatinine clearance(CrCl)using the Cockcroft-Gault formula.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zoledronic acid</intervention_name>
    <description>Zoledronic acid (Zometa) 4mg IV every 4 weeks for 3 treatments with chemotherapy as selected by treating physician</description>
    <arm_group_label>Zoledronic Acid</arm_group_label>
    <other_name>Zometa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically documented non-small cell lung cancer, Stages 3B, 4 or recurrent

          -  Pleural effusion cytologically proven to be malignant

          -  0 or 1 prior chemotherapy regimens for non-small cell lung cancer (adjuvant
             chemotherapy post resection, or concurrent chemo-radiation therapy counts as one
             regimen regardless of number of agents used.)

          -  Planning to start chemotherapy for non-small cell lung cancer (treatment regimen at
             discretion of treating physician but must include one or more of the following
             agents:cisplatin,carboplatin,docetaxel,paclitaxel, pemetrexed,gemcitabine,vinorelbine)
             Patients may receive anti-angiogenesis agents (bevacizumab) in addition to
             chemotherapy, but patients treated solely with tyrosine kinase inhibitors or
             growth-factor receptor blockers are not eligible.

          -  Prior radiation therapy is permitted.

          -  Performance status 0,1,2

          -  Serum creatinine less than 2.0 or estimated creatinine clearance over 30cc/min by
             Calcroft/Gault equation

          -  Estimated life expectancy over 3 months

          -  Signed informed consent

          -  Age greater than 18 years

          -  Patients who have clinical indication for Zometa treatment such as lytic bone
             metastases or hypercalcemia can be included

        Exclusion Criteria:

          -  Pregnant or lactating

          -  Patient with concurrent medical or psychiatric illness which would, in the opinion of
             the investigator, prevent compliance with the study

          -  Patients who undergo any procedure other than thoracentesis for drainage of
             effusion.Patients may have had more than one thoracentesis prior to study. Patients
             who have large bore chest tube placement, permanent transthoracic catheter (Pleurex),
             medical pleurodesis or thoracoscopy are excluded.

          -  Current active dental problems including infection of the teeth or jawbone (maxilla or
             mandibular);dental or fixture trauma, or a current or prior diagnosis of osteonecrosis
             of the jaw (ONJ), of exposed bone in the mouth, or of slow healing after dental
             procedures.

          -  Recent (within 6 weeks)or planned dental or jaw surgery (e.g.extraction, implants).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Todd Sheppard, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rochester General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Bushunow, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rochester General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kevin Lightner, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rochester General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rochester General Hospital</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 29, 2009</study_first_submitted>
  <study_first_submitted_qc>October 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2009</study_first_posted>
  <results_first_submitted>August 14, 2012</results_first_submitted>
  <results_first_submitted_qc>November 5, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 4, 2012</results_first_posted>
  <last_update_submitted>November 5, 2012</last_update_submitted>
  <last_update_submitted_qc>November 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Rochester General Hospital</investigator_affiliation>
    <investigator_full_name>Peter Bushunow MD</investigator_full_name>
    <investigator_title>Director, Oncology Research</investigator_title>
  </responsible_party>
  <keyword>malignant pleural effusion</keyword>
  <keyword>non small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Pleural Effusion</mesh_term>
    <mesh_term>Pleural Effusion, Malignant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zoledronic acid</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Zoledronic Acid</title>
          <description>Monthly zoledronic acid in addition to chemotherapy. Zoledronic acid dose per package insert for up to 4 cycles.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Zoledronic Acid</title>
          <description>Monthly zoledronic acid in addition to chemotherapy</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>control of malignant pleural effusions in non small cell lung cancer</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of Control (Lack of Need for Palliative Intervention of Malignant Pleural Effusions) in Patients With Non Small Cell Lung Cancer Treated With Standard Regimens of Cytotoxic Chemotherapy With the Addition of Zometa</title>
        <time_frame>3 months</time_frame>
        <population>Too few patients enrolled to analyze data</population>
        <group_list>
          <group group_id="O1">
            <title>Zoledronic Acid</title>
            <description>Monthly zoledronic acid in addition to chemotherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Control (Lack of Need for Palliative Intervention of Malignant Pleural Effusions) in Patients With Non Small Cell Lung Cancer Treated With Standard Regimens of Cytotoxic Chemotherapy With the Addition of Zometa</title>
          <population>Too few patients enrolled to analyze data</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Although the protocol was approved to begin enrollment 9/25/09, Adverse event data was collected from first patient enrollment 1/4/10-through study termination on 4/26/11. Aproximately 1 year, 4 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Zoledronic Acid</title>
          <description>Monthly zoledronic acid in addition to chemotherapy</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Admitted to hospital with diagnosis of pneumonia and anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>erythematous prurtic rash over chest and abdomen</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Todd Sheppard, MD</name_or_title>
      <organization>Rochester General Hospital</organization>
      <phone>585-922-4409</phone>
      <email>todd.sheppard@rochestergeneral.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

